Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

Chloe Kelly endured a difficult time when she looked to leave Manchester City for Arsenal and the forward now revealed how her health suffered during that period ...

Absci Corporation (NASDAQ:ABSI) is one of the best multibagger penny stocks to buy right now. On December 12, Needham’s Gil ...

Nektar Therapeutics may have a pipeline-in-a-drug with rezpegaldesleukin, has additional readouts ahead, and cash until 2027.

But in recent years, social media users have claimed in Reddit threads, TikTok videos and Instagram reels that the ingredient ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

Here are the top 5 most-viewed alopecia content in 2025.

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...

A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...